Medipharm Labs Revenues Crater 64.5% Quarter Over Quarter To $4.9 Million
It appears that not all operators are able to successfully perform under the changing market conditions within the cannabis landscape.
Read moreIt appears that not all operators are able to successfully perform under the changing market conditions within the cannabis landscape.
Read moreIn response to the spread of COVID-19, the Canadian Federal Government introduced several programs to try and alleviate the economic
Read moreMedipharm Labs (TSX: LABS) this morning announced changes to their leadership team within a brief news release that was issued.
Read moreOn Monday Medipharm Labs (TSX: LABS) announced an exclusive medical cannabis partnership with the European pharmaceutical company STADA. Under the
Read moreFriday evening following the close of markets, a note was sent out by PI Financials to those of whom receive
Read moreMedipharm Labs (TSX: LABS) continues to expand its international presence, this morning announcing that it has signed a white label
Read moreLast week, Medipharm Labs (TSX: LABS) reported their second-quarter earnings. Revenue came in at $13.9 million, a 25% increase quarter
Read moreMedipharm Labs (TSX: LABS) reported further disappointing quarterly results this morning, with revenues of $13.9 million being recorded for the
Read moreAs a follow up to the earlier covered resumption of coverage by Canaccord Genuity on The Valens Company (TSX: VLNS),
Read moreOf the 100 companies in the BI Global Cannabis Competitive Peers index tracked in 2019, The Valens Company (TSX: VLNS)
Read more